Systemic Inflammation and Arrhythmogenesis: A Review of Mechanistic and Clinical Perspectives

Angiology

Volumn 69, Issue 4, 2018, Pages 288-296

  Yalta, Tulin ^a   Yalta, Kenan ^a  

^a TRAKYA UNIVERSITY   (Turkey)

Author keywords

arrhythmogenesis; clinical implications; potential mechanisms; potential triggers; systemic inflammation

Indexed keywords

ANTIINFLAMMATORY AGENT; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CYTOKINE; FIBRINOGEN; INTERLEUKIN 1; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR; BIOLOGICAL MARKER;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ADRENERGIC STIMULATION; ARRHYTHMOGENESIS; ATRIAL FIBRILLATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CONGESTIVE CARDIOMYOPATHY; CORONARY ARTERY BYPASS GRAFT; ELECTROCARDIOGRAPHY; HEART FAILURE; HEART RATE VARIABILITY; HEART VENTRICLE TACHYCARDIA; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; OXIDATIVE STRESS; PERFUSION; REVIEW; SENSITIVITY AND SPECIFICITY; COMPLICATION; HEART ARRHYTHMIA; METABOLISM; PATHOPHYSIOLOGY; PROGNOSIS;

ARRHYTHMIAS, CARDIAC; BIOMARKERS; HUMANS; INFLAMMATION; PROGNOSIS;

EID: 85032286896     PISSN: 00033197     EISSN: 19401574     Source Type: Journal    
DOI: 10.1177/0003319717709380     Document Type: Review

References (57)

1. Nyström PO. The systemic inflammatory response syndrome: definitions and aetiology. J Antimicrob Chemother. 1998;41(suppl A):1–7.
2. Ljung L, Askling J, Rantapää-Dahlqvist S, Jacobsson L. The risk of acute coronary syndrome in rheumatoid arthritis in relation to tumour necrosis factor inhibitors and the risk in the general population: a national cohort study. Arthritis Res Ther. 2014;16(3):R127.
3. Corrales-Medina VF, Madjid M, Musher DM. Role of acute infection in triggering acute coronary syndromes. Lancet Infect Dis. 2010;10(2):83–92.
4. Dong M, Liu T, Li G. Association between acute infections and risk of acute coronary syndrome: a meta-analysis. Int J Cardiol. 2011;147(3):479–482.
5. Warren-Gash C, Smeeth L, Hayward AC. Influenza as a trigger for acute myocardial infarction or death from cardiovascular disease: a systematic review. Lancet Infect Dis. 2009;9(10):601–610.
6. Yalta K, Sivri N, Yetkin E. Acute coronary syndromes in the setting of acute infections: is there an overdiagnosis with overtreatment? Int J Cardiol. 2011;149(3):383.
7. Ruiz-Bailén M, Romero-Bermejo FJ, Rucabado-Aguilar L. Myocardial dysfunction in the critically ill patient: is it really reversible? Int J Cardiol. 2010;145(3):615–616.
8. Liew R, Khairunnisa K, Gu Y. Role of tumor necrosis factor-α in the pathogenesis of atrial fibrosis and development of an arrhythmogenic substrate. Circ J. 2013;77(5):1171–1179.
9. Guo Y, Lip GY, Apostolakis S. Inflammation in atrial fibrillation. J Am Coll Cardiol. 2012;60(22):2263–2270.
10. Yalta K, Geyik B, Sıvrı N, Yetkın E. Meteorologic factors may trigger arrhythmogenesis through induction of systemic inflammation and coagulation response: potential antiarrhythmic benefits of mitigating this response in arrhythmia-prone subjects under poor meteorologic conditions? Int J Cardiol. 2013;168(5):4937–4938.
11. Yalta K, Sivri N, Geyik B, Yetkin E. Tumour necrosis factor-α antagonism: a potential therapeutic target for prevention of arrhythmogenesis in the setting of acute myocardial infarction? Heart. 2014;100(3):263.
12. Maier W, Altwegg LA, Corti R. Inflammatory markers at the site of ruptured plaque in acute myocardial infarction: locally increased interleukin-6 and serum amyloid A but decreased C-reactive protein. Circulation. 2005;111(11):1355–1361.
13. Satoh M, Ishikawa Y, Itoh T, Minami Y, Takahashi Y, Nakamura M. The expression of TNF-alpha converting enzyme at the site of ruptured plaques in patients with acute myocardial infarction. Eur J Clin Invest. 2008;38(2):97–105.
14. Cusack MR, Marber MS, Lambiase PD, Bucknall CA, Redwood SR. Systemic inflammation in unstable angina is the result of myocardial necrosis. J Am Coll Cardiol. 2002;39(12):1917–1923.
15. Fahim MR, Halim SM, Kamel I. Tumor necrosis factor alpha in patients with acute myocardial infarction. Egypt J Immunol. 2004;11(1):31–37.
16. Yalta K, Yılmaz MB, Turgut OO, Tandogan I. Markers of inflammation and thrombin generation: additional guides in determining the therapeutic strategy for malign ventricular arrhythmias after an acute myocardial infarction? Int J Cardiol. 2010;145(3):492–493.
17. Okazaki R, Iwasaki YK, Miyauchi Y. Lipopolysaccharide induces atrial arrhythmogenesis via down-regulation of L-type Ca2+ channel genes in rats. Int Heart J. 2009;50(3):353–363.
18. Court O, Kumar A, Parrillo JE, Kumar A. Clinical review: myocardial depression in sepsis and septic shock. Crit Care. 2002;6(6):500–508.
19. van den Oever IA, Sattar N, Nurmohamed MT. Thromboembolic and cardiovascular risk in rheumatoid arthritis: role of the haemostatic system. Ann Rheum Dis. 2014;73(6):954–957.
20. McInnes IB, Thompson L, Giles JT. Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study [published online 2013]. Ann Rheum Dis. 2015;74(4):694–702. doi: 10.1136/annrheumdis-2013-204345.
21. Alonso A, Tang W, Agarwal SK, Soliman EZ, Chamberlain AM, Folsom AR. Hemostatic markers are associated with the risk and prognosis of atrial fibrillation: the ARIC study. Int J Cardiol. 2012;155(2):217–222.
22. Mukamal KJ, Tolstrup JS, Friberg J, Grønbaek M, Jensen G. Fibrinogen and albumin levels and risk of atrial fibrillation in men and women (the Copenhagen City Heart Study). Am J Cardiol. 2006;98(1):75–81.
23. Elmas E, Kaelsch T, Wolpert C. Assessment of markers of thrombin generation in patients with acute myocardial infarction complicated by ventricular fibrillation. Clin Cardiol. 2006;29(4):165–169.
24. Wu N, Xu B, Xiang Y. Association of inflammatory factors with occurrence and recurrence of atrial fibrillation: a meta-analysis. Int J Cardiol. 2013;169(1):62–72.
25. Jiang Z, Dai L, Song Z, Li H, Shu M. Association between C-reactive protein and atrial fibrillation recurrence after catheter ablation: a meta-analysis. Clin Cardiol. 2013;36(9):548–554.
26. Yo CH, Lee SH, Chang SS, Lee MC, Lee CC. Value of high-sensitivity C-reactive protein assays in predicting atrial fibrillation recurrence: a systematic review and meta-analysis. BMJ Open. 2014;4(2):e004418.
27. Sinner MF, Stepas KA, Moser CB. B-type natriuretic peptide and C-reactive protein in the prediction of atrial fibrillation risk: the CHARGE-AF Consortium of community-based cohort studies [published online July 18, 2014]. Europace. 2014;16(10):1426–1433.
28. Cheng T, Wang XF, Hou YT, Zhang L. Correlation between atrial fibrillation, serum amyloid protein A and other inflammatory cytokines. Mol Med Rep. 2012;6(3):581–584.
29. Barassi A, Pezzilli R, Morselli-Labate AM. Serum amyloid A and C-reactive protein independently predict the recurrences of atrial fibrillation after cardioversion in patients with preserved left ventricular function. Can J Cardiol. 2012;28(5):537–541.
30. Streitner F, Kuschyk J, Veltmann C. Role of proinflammatory markers and NT-proBNP in patients with an implantable cardioverter-defibrillator and an electrical storm. Cytokine. 2009;47(3):166–172.
31. Streitner F, Kuschyk J, Veltmann C. Prospective study of interleukin-6 and the risk of malignant ventricular tachyarrhythmia in ICD-recipients—a pilot study. Cytokine. 2007;40(1):30–34.
32. Konstantino Y, Kusniec J, Reshef T. Inflammatory biomarkers are not predictive of intermediate-term risk of ventricular tachyarrhythmias in stable CHF patients. Clin Cardiol. 2007;30(8):408–413.
33. Szydlowski L, Skierska A, Markiewicz-Loskot G, Mazurek B, Morka A, Undas A. The role of Interleukin-6, its -174 G>C polymorphism and C-reactive protein in idiopathic cardiac arrhythmias in children. Adv Med Sci. 2013;58(2):320–325.
34. Elmas E, Lang S, Dempfle CE. High plasma levels of tissue inhibitor of metalloproteinase-1 (TIMP-1) and interleukin-8 (IL-8) characterize patients prone to ventricular fibrillation complicating myocardial infarction. Clin Chem Lab Med. 2007;45(10):1360–1365.
35. Xiao H, Liao YH, Chen ZJ. Tumor necrosis factor-alpha: a new mechanism of ischemic ventricular fibrillation? Chin Med J (Engl). 2008;121(18):1848–1851.
36. Lee SH, Chen YC, Chen YJ. Tumor necrosis factor-alpha alters calcium handling and increases arrhythmogenesis of pulmonary vein cardiomyocytes. Life Sci. 2007;80(19):1806–1815.
37. Duncan DJ, Yang Z, Hopkins PM, Steele DS, Harrison SM. TNF-alpha and IL-1beta increase Ca2+ leak from the sarcoplasmic reticulum and susceptibility to arrhythmia in rat ventricular myocytes. Cell Calcium. 2010;47(4):378–386.
38. Grandy SA, Brouillette J, Fiset C. Reduction of ventricular sodium current in a mouse model of HIV. J Cardiovasc Electrophysiol. 2010;21(8):916–922.
39. Steptoe A, Molloy GJ, Messerli-Bürgy N. Fear of dying and inflammation following acute coronary syndrome. Eur Heart J. 2011;32(19):2405–2411.
40. Panoulas VF, Toms TE, Douglas KM. Prolonged QTc interval predicts all-cause mortality in patients with rheumatoid arthritis: an association driven by high inflammatory burden. Rheumatology (Oxford). 2014;53(1):131–137.
41. Acar GR, Akkoyun M, Nacar AB. Evaluation of Tp-e interval and Tp-e/QT ratio in patients with rheumatoid arthritis. Turk Kardiyol Dern Ars. 2014;42(1):29–34.
42. Alexander C, Rietschel ET. Bacterial lipopolysaccharides and innate immunity. J Endotoxin Res. 2001;7(3):167–202.
43. Zhong J, Hwang TC, Adams HR, Rubin LJ. Reduced L-type calcium current in ventricular myocytes from endotoxemic guinea pigs. Am J Physiol. 1997;273(5 Pt 2):H2312–H2324.
44. Lew WY, Yasuda S, Yuan T, Hammond HK. Endotoxin-induced cardiac depression is associated with decreased cardiac dihydropyridine receptors in rabbits. J Mol Cell Cardiol. 1996;28(6):1367–1371.
45. Calò L, Martino A, Tota C. The anti-arrhythmic effects of n-3 PUFAs. Int J Cardiol. 2013;170(2 suppl 1):S21–S27.
46. Liu T, Korantzopoulos P, Li G. Antioxidant therapies for the management of atrial fibrillation. Cardiovasc Diagn Ther. 2012;2(4):298–307.
47. Granier M, Massin F, Pasquié JL. Pro- and anti-arrhythmic effects of anti-inflammatory drugs. Antiinflamm Antiallergy Agents Med Chem. 2013;12(1):83–93.
48. Koyama T, Tada H, Sekiguchi Y. Prevention of atrial fibrillation recurrence with corticosteroids after radiofrequency catheter ablation: a randomized controlled trial. J Am Coll Cardiol. 2010;56(18):1463–1472.
49. Cheruku KK, Ghani A, Ahmad F. Efficacy of nonsteroidal anti-inflammatory medications for prevention of atrial fibrillation following coronary artery bypass graft surgery. Prev Cardiol. 2004;7(1):13–18.
50. Mathew JP, Fontes ML, Tudor IC, ; Investigators of the ischemia research and education foundation; multicenter study of perioperative ischemia research group. A multicenter risk index for atrial fibrillation after cardiac surgery. JAMA. 2004;291(14):1720–1729.
51. Schmidt M, Christiansen CF, Mehnert F, Rothman KJ, Sørensen HT. Non-steroidal anti-inflammatory drug use and risk of atrial fibrillation or flutter: population based case-control study. BMJ. 2011;343:d3450.
52. Deftereos S, Giannopoulos G, Kossyvakis C. Colchicine for prevention of early atrial fibrillation recurrence after pulmonary vein isolation: a randomized controlled study. J Am Coll Cardiol. 2012;60(18):1790–1796.
53. Imazio M, Brucato A, Ferrazzi P. Colchicine reduces postoperative atrial fibrillation: results of the Colchicine for the Prevention of the Postpericardiotomy Syndrome (COPPS) atrial fibrillation substudy. Circulation. 2011;124(21):2290–2295.
54. Imazio M, Brucato A, Ferrazzi P, ; COPPS-2 Investigators. Colchicine for prevention of postpericardiotomy syndrome and postoperative atrial fibrillation: the COPPS-2 randomized clinical trial. JAMA. 2014;312(10):1016–1023.
55. Trivedi C, Sadadia M. Colchicine in prevention of atrial fibrillation following cardiac surgery: systematic review and meta-analysis. Indian J Pharmacol. 2014;46(6):590–595.
56. Awan Z, Genest J. Inflammation modulation and cardiovascular disease prevention [published online April 7, 2014]. Eur J Prev Cardiol. 2015;22(6):719–733. doi:10.1177/2047487314529350.
57. Padfield GJ, Din JN, Koushiappi E. Cardiovascular effects of tumour necrosis factor α antagonism in patients with acute myocardial infarction: a first in human study. Heart. 2013;99(18):1330–1335.